Life-supporting Kidney Xenotransplantation From Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens.
Identifieur interne : 000300 ( Main/Exploration ); précédent : 000299; suivant : 000301Life-supporting Kidney Xenotransplantation From Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens.
Auteurs : Takayuki Yamamoto [États-Unis] ; Hidetaka Hara [États-Unis] ; Jeremy Foote [États-Unis] ; Liaoran Wang [États-Unis, République populaire de Chine] ; Qi Li [États-Unis, République populaire de Chine] ; Edwin C. Klein [États-Unis] ; Hendrik Jan Schuurman [Pays-Bas] ; Hongmin Zhou [États-Unis, République populaire de Chine] ; Juan Li [États-Unis, République populaire de Chine] ; A Joseph Tector [États-Unis] ; Zhongqiang Zhang [États-Unis, République populaire de Chine] ; Mohamed Ezzelarab [États-Unis] ; Ray Lovingood [États-Unis] ; David Ayares [États-Unis] ; Devin E. Eckhoff [États-Unis] ; David K C. Cooper [États-Unis] ; Hayato Iwase [États-Unis]Source :
- Transplantation [ 1534-6080 ] ; 2019.
Descripteurs français
- KwdFr :
- Animal génétiquement modifié (MeSH), Animaux (MeSH), Anticorps monoclonaux (administration et posologie), Antigènes CD40 (antagonistes et inhibiteurs), Antigènes CD40 (immunologie), Antigènes CD46 (génétique), Galactosyltransferases (génétique), Humains (MeSH), Hétérogreffes (effets des médicaments et des substances chimiques), Hétérogreffes (immunologie), Immunosuppresseurs (administration et posologie), Modèles animaux de maladie humaine (MeSH), Papio (MeSH), Rein (effets des médicaments et des substances chimiques), Rein (immunologie), Rejet du greffon (immunologie), Rejet du greffon (mortalité), Rejet du greffon (prévention et contrôle), Soins de maintien des fonctions vitales (méthodes), Suidae (génétique), Survie du greffon (effets des médicaments et des substances chimiques), Survie du greffon (immunologie), Techniques de knock-out de gènes (MeSH), Transplantation hétérologue (effets indésirables), Transplantation rénale (effets indésirables), Transplantation rénale (méthodes), Transplants (effets des médicaments et des substances chimiques), Transplants (immunologie).
- MESH :
- administration et posologie : Anticorps monoclonaux, Immunosuppresseurs.
- antagonistes et inhibiteurs : Antigènes CD40.
- effets des médicaments et des substances chimiques : Hétérogreffes, Rein, Survie du greffon, Transplants.
- effets indésirables : Transplantation hétérologue, Transplantation rénale.
- génétique : Antigènes CD46, Galactosyltransferases, Suidae.
- immunologie : Antigènes CD40, Hétérogreffes, Rein, Rejet du greffon, Survie du greffon, Transplants.
- mortalité : Rejet du greffon.
- méthodes : Soins de maintien des fonctions vitales, Transplantation rénale.
- prévention et contrôle : Rejet du greffon.
- Animal génétiquement modifié, Animaux, Humains, Modèles animaux de maladie humaine, Papio, Techniques de knock-out de gènes.
English descriptors
- KwdEn :
- Animals (MeSH), Animals, Genetically Modified (MeSH), Antibodies, Monoclonal (administration & dosage), CD40 Antigens (antagonists & inhibitors), CD40 Antigens (immunology), Disease Models, Animal (MeSH), Galactosyltransferases (genetics), Gene Knockout Techniques (MeSH), Graft Rejection (immunology), Graft Rejection (mortality), Graft Rejection (prevention & control), Graft Survival (drug effects), Graft Survival (immunology), Heterografts (drug effects), Heterografts (immunology), Humans (MeSH), Immunosuppressive Agents (administration & dosage), Kidney (drug effects), Kidney (immunology), Kidney Transplantation (adverse effects), Kidney Transplantation (methods), Life Support Care (methods), Membrane Cofactor Protein (genetics), Papio (MeSH), Swine (genetics), Transplantation, Heterologous (adverse effects), Transplants (drug effects), Transplants (immunology).
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Immunosuppressive Agents.
- chemical , antagonists & inhibitors : CD40 Antigens.
- chemical , genetics : Galactosyltransferases, Membrane Cofactor Protein.
- chemical , immunology : CD40 Antigens.
- adverse effects : Kidney Transplantation, Transplantation, Heterologous.
- drug effects : Graft Survival, Heterografts, Kidney, Transplants.
- genetics : Swine.
- immunology : Graft Rejection, Graft Survival, Heterografts, Kidney, Transplants.
- methods : Kidney Transplantation, Life Support Care.
- mortality : Graft Rejection.
- prevention & control : Graft Rejection.
- Animals, Animals, Genetically Modified, Disease Models, Animal, Gene Knockout Techniques, Humans, Papio.
Abstract
BACKGROUND
The aims of this study were to evaluate the efficacy of US Food and Drug Administration-approved drugs in genetically engineered pig-to-baboon kidney xenotransplantation and compare the results with those using an anti-CD40 monoclonal antibody (mAb)-based regimen.
METHODS
Ten life-supporting kidney transplants were carried out in baboons using α1,3-galactosyltransferase gene-knockout/CD46 pigs with various other genetic manipulations aimed at controlling coagulation dysregulation. Eight transplants resulted in informative data. Immunosuppressive therapy consisted of induction with antithymocyte globulin and anti-CD20mAb, and maintenance based on either (1) CTLA4-Ig and/or tacrolimus (+rapamycin or mycophenolate mofetil) (GroupA [US Food and Drug Administration-approved regimens], n = 4) or (2) anti-CD40mAb + rapamycin (GroupB, n = 4). All baboons received corticosteroids, interleukin-6R blockade, and tumor necrosis factor-α blockade. Baboons were followed by clinical and laboratory monitoring of kidney function, coagulation, and immune parameters. At euthanasia, morphological and immunohistochemical studies were performed on the kidney grafts.
RESULTS
The median survival in GroupB was 186 days (range 90-260), which was significantly longer than in GroupA; median 14 days (range 12-32) (P < 0.01). Only GroupA baboons developed consumptive coagulopathy and the histopathological features of thrombotic microangiopathic glomerulopathy and interstitial arterial vasculitis.
CONCLUSIONS
Recognizing that the pig donors in each group differed in some genetic modifications, these data indicate that maintenance immunosuppression including anti-CD40mAb may be important to prevent pig kidney graft failure.
DOI: 10.1097/TP.0000000000002796
PubMed: 31283686
Affiliations:
- Pays-Bas, République populaire de Chine, États-Unis
- Alabama, Hubei, Pennsylvanie, Utrecht (province), Virginie
- Utrecht, Wuhan
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Life-supporting Kidney Xenotransplantation From Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens.</title><author><name sortKey="Yamamoto, Takayuki" sort="Yamamoto, Takayuki" uniqKey="Yamamoto T" first="Takayuki" last="Yamamoto">Takayuki Yamamoto</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Hara, Hidetaka" sort="Hara, Hidetaka" uniqKey="Hara H" first="Hidetaka" last="Hara">Hidetaka Hara</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Foote, Jeremy" sort="Foote, Jeremy" uniqKey="Foote J" first="Jeremy" last="Foote">Jeremy Foote</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Animal Resources Program, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Department of Microbiology and Animal Resources Program, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Liaoran" sort="Wang, Liaoran" uniqKey="Wang L" first="Liaoran" last="Wang">Liaoran Wang</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Second Affiliated Hospital, University of South China, Hengyang City, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Li, Qi" sort="Li, Qi" uniqKey="Li Q" first="Qi" last="Li">Qi Li</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Second Affiliated Hospital, University of South China, Hengyang City, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Klein, Edwin C" sort="Klein, Edwin C" uniqKey="Klein E" first="Edwin C" last="Klein">Edwin C. Klein</name><affiliation wicri:level="2"><nlm:affiliation>Division of Laboratory Animal Resources, University of Pittsburgh, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Laboratory Animal Resources, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Schuurman, Hendrik Jan" sort="Schuurman, Hendrik Jan" uniqKey="Schuurman H" first="Hendrik Jan" last="Schuurman">Hendrik Jan Schuurman</name><affiliation wicri:level="3"><nlm:affiliation>Schubiomed Consultancy, Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Schubiomed Consultancy, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Zhou, Hongmin" sort="Zhou, Hongmin" uniqKey="Zhou H" first="Hongmin" last="Zhou">Hongmin Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Cardiothoracic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiothoracic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan</wicri:regionArea><placeName><settlement type="city">Wuhan</settlement><region type="région">Hubei</region></placeName></affiliation></author><author><name sortKey="Li, Juan" sort="Li, Juan" uniqKey="Li J" first="Juan" last="Li">Juan Li</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Second Affiliated Hospital, University of South China, Hengyang City, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Tector, A Joseph" sort="Tector, A Joseph" uniqKey="Tector A" first="A Joseph" last="Tector">A Joseph Tector</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Zhang, Zhongqiang" sort="Zhang, Zhongqiang" uniqKey="Zhang Z" first="Zhongqiang" last="Zhang">Zhongqiang Zhang</name><affiliation wicri:level="2"><nlm:affiliation>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of General Surgery and Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of General Surgery and Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Ezzelarab, Mohamed" sort="Ezzelarab, Mohamed" uniqKey="Ezzelarab M" first="Mohamed" last="Ezzelarab">Mohamed Ezzelarab</name><affiliation wicri:level="2"><nlm:affiliation>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Lovingood, Ray" sort="Lovingood, Ray" uniqKey="Lovingood R" first="Ray" last="Lovingood">Ray Lovingood</name><affiliation wicri:level="2"><nlm:affiliation>Kirklin Clinic Pharmacy, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Kirklin Clinic Pharmacy, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Ayares, David" sort="Ayares, David" uniqKey="Ayares D" first="David" last="Ayares">David Ayares</name><affiliation wicri:level="2"><nlm:affiliation>Revivicor, Blacksburg, VA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Revivicor, Blacksburg</wicri:cityArea></affiliation></author><author><name sortKey="Eckhoff, Devin E" sort="Eckhoff, Devin E" uniqKey="Eckhoff D" first="Devin E" last="Eckhoff">Devin E. Eckhoff</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Cooper, David K C" sort="Cooper, David K C" uniqKey="Cooper D" first="David K C" last="Cooper">David K C. Cooper</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Iwase, Hayato" sort="Iwase, Hayato" uniqKey="Iwase H" first="Hayato" last="Iwase">Hayato Iwase</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31283686</idno><idno type="pmid">31283686</idno><idno type="doi">10.1097/TP.0000000000002796</idno><idno type="wicri:Area/Main/Corpus">000236</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000236</idno><idno type="wicri:Area/Main/Curation">000236</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000236</idno><idno type="wicri:Area/Main/Exploration">000236</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Life-supporting Kidney Xenotransplantation From Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens.</title><author><name sortKey="Yamamoto, Takayuki" sort="Yamamoto, Takayuki" uniqKey="Yamamoto T" first="Takayuki" last="Yamamoto">Takayuki Yamamoto</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Hara, Hidetaka" sort="Hara, Hidetaka" uniqKey="Hara H" first="Hidetaka" last="Hara">Hidetaka Hara</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Foote, Jeremy" sort="Foote, Jeremy" uniqKey="Foote J" first="Jeremy" last="Foote">Jeremy Foote</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Animal Resources Program, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Department of Microbiology and Animal Resources Program, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Liaoran" sort="Wang, Liaoran" uniqKey="Wang L" first="Liaoran" last="Wang">Liaoran Wang</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Second Affiliated Hospital, University of South China, Hengyang City, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Li, Qi" sort="Li, Qi" uniqKey="Li Q" first="Qi" last="Li">Qi Li</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Second Affiliated Hospital, University of South China, Hengyang City, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Klein, Edwin C" sort="Klein, Edwin C" uniqKey="Klein E" first="Edwin C" last="Klein">Edwin C. Klein</name><affiliation wicri:level="2"><nlm:affiliation>Division of Laboratory Animal Resources, University of Pittsburgh, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Laboratory Animal Resources, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Schuurman, Hendrik Jan" sort="Schuurman, Hendrik Jan" uniqKey="Schuurman H" first="Hendrik Jan" last="Schuurman">Hendrik Jan Schuurman</name><affiliation wicri:level="3"><nlm:affiliation>Schubiomed Consultancy, Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Schubiomed Consultancy, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Zhou, Hongmin" sort="Zhou, Hongmin" uniqKey="Zhou H" first="Hongmin" last="Zhou">Hongmin Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Cardiothoracic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiothoracic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan</wicri:regionArea><placeName><settlement type="city">Wuhan</settlement><region type="région">Hubei</region></placeName></affiliation></author><author><name sortKey="Li, Juan" sort="Li, Juan" uniqKey="Li J" first="Juan" last="Li">Juan Li</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Second Affiliated Hospital, University of South China, Hengyang City, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Tector, A Joseph" sort="Tector, A Joseph" uniqKey="Tector A" first="A Joseph" last="Tector">A Joseph Tector</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Zhang, Zhongqiang" sort="Zhang, Zhongqiang" uniqKey="Zhang Z" first="Zhongqiang" last="Zhang">Zhongqiang Zhang</name><affiliation wicri:level="2"><nlm:affiliation>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of General Surgery and Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of General Surgery and Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Ezzelarab, Mohamed" sort="Ezzelarab, Mohamed" uniqKey="Ezzelarab M" first="Mohamed" last="Ezzelarab">Mohamed Ezzelarab</name><affiliation wicri:level="2"><nlm:affiliation>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Lovingood, Ray" sort="Lovingood, Ray" uniqKey="Lovingood R" first="Ray" last="Lovingood">Ray Lovingood</name><affiliation wicri:level="2"><nlm:affiliation>Kirklin Clinic Pharmacy, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Kirklin Clinic Pharmacy, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Ayares, David" sort="Ayares, David" uniqKey="Ayares D" first="David" last="Ayares">David Ayares</name><affiliation wicri:level="2"><nlm:affiliation>Revivicor, Blacksburg, VA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Revivicor, Blacksburg</wicri:cityArea></affiliation></author><author><name sortKey="Eckhoff, Devin E" sort="Eckhoff, Devin E" uniqKey="Eckhoff D" first="Devin E" last="Eckhoff">Devin E. Eckhoff</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Cooper, David K C" sort="Cooper, David K C" uniqKey="Cooper D" first="David K C" last="Cooper">David K C. Cooper</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Iwase, Hayato" sort="Iwase, Hayato" uniqKey="Iwase H" first="Hayato" last="Iwase">Hayato Iwase</name><affiliation wicri:level="2"><nlm:affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author></analytic><series><title level="j">Transplantation</title><idno type="eISSN">1534-6080</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Animals, Genetically Modified (MeSH)</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>CD40 Antigens (antagonists & inhibitors)</term><term>CD40 Antigens (immunology)</term><term>Disease Models, Animal (MeSH)</term><term>Galactosyltransferases (genetics)</term><term>Gene Knockout Techniques (MeSH)</term><term>Graft Rejection (immunology)</term><term>Graft Rejection (mortality)</term><term>Graft Rejection (prevention & control)</term><term>Graft Survival (drug effects)</term><term>Graft Survival (immunology)</term><term>Heterografts (drug effects)</term><term>Heterografts (immunology)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (administration & dosage)</term><term>Kidney (drug effects)</term><term>Kidney (immunology)</term><term>Kidney Transplantation (adverse effects)</term><term>Kidney Transplantation (methods)</term><term>Life Support Care (methods)</term><term>Membrane Cofactor Protein (genetics)</term><term>Papio (MeSH)</term><term>Swine (genetics)</term><term>Transplantation, Heterologous (adverse effects)</term><term>Transplants (drug effects)</term><term>Transplants (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animal génétiquement modifié (MeSH)</term><term>Animaux (MeSH)</term><term>Anticorps monoclonaux (administration et posologie)</term><term>Antigènes CD40 (antagonistes et inhibiteurs)</term><term>Antigènes CD40 (immunologie)</term><term>Antigènes CD46 (génétique)</term><term>Galactosyltransferases (génétique)</term><term>Humains (MeSH)</term><term>Hétérogreffes (effets des médicaments et des substances chimiques)</term><term>Hétérogreffes (immunologie)</term><term>Immunosuppresseurs (administration et posologie)</term><term>Modèles animaux de maladie humaine (MeSH)</term><term>Papio (MeSH)</term><term>Rein (effets des médicaments et des substances chimiques)</term><term>Rein (immunologie)</term><term>Rejet du greffon (immunologie)</term><term>Rejet du greffon (mortalité)</term><term>Rejet du greffon (prévention et contrôle)</term><term>Soins de maintien des fonctions vitales (méthodes)</term><term>Suidae (génétique)</term><term>Survie du greffon (effets des médicaments et des substances chimiques)</term><term>Survie du greffon (immunologie)</term><term>Techniques de knock-out de gènes (MeSH)</term><term>Transplantation hétérologue (effets indésirables)</term><term>Transplantation rénale (effets indésirables)</term><term>Transplantation rénale (méthodes)</term><term>Transplants (effets des médicaments et des substances chimiques)</term><term>Transplants (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>CD40 Antigens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Galactosyltransferases</term><term>Membrane Cofactor Protein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>CD40 Antigens</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Immunosuppresseurs</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Kidney Transplantation</term><term>Transplantation, Heterologous</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Antigènes CD40</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Graft Survival</term><term>Heterografts</term><term>Kidney</term><term>Transplants</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Hétérogreffes</term><term>Rein</term><term>Survie du greffon</term><term>Transplants</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Transplantation hétérologue</term><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Swine</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes CD46</term><term>Galactosyltransferases</term><term>Suidae</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes CD40</term><term>Hétérogreffes</term><term>Rein</term><term>Rejet du greffon</term><term>Survie du greffon</term><term>Transplants</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Graft Rejection</term><term>Graft Survival</term><term>Heterografts</term><term>Kidney</term><term>Transplants</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Kidney Transplantation</term><term>Life Support Care</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Graft Rejection</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Rejet du greffon</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Soins de maintien des fonctions vitales</term><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Graft Rejection</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Rejet du greffon</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Animals, Genetically Modified</term><term>Disease Models, Animal</term><term>Gene Knockout Techniques</term><term>Humans</term><term>Papio</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animal génétiquement modifié</term><term>Animaux</term><term>Humains</term><term>Modèles animaux de maladie humaine</term><term>Papio</term><term>Techniques de knock-out de gènes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The aims of this study were to evaluate the efficacy of US Food and Drug Administration-approved drugs in genetically engineered pig-to-baboon kidney xenotransplantation and compare the results with those using an anti-CD40 monoclonal antibody (mAb)-based regimen.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Ten life-supporting kidney transplants were carried out in baboons using α1,3-galactosyltransferase gene-knockout/CD46 pigs with various other genetic manipulations aimed at controlling coagulation dysregulation. Eight transplants resulted in informative data. Immunosuppressive therapy consisted of induction with antithymocyte globulin and anti-CD20mAb, and maintenance based on either (1) CTLA4-Ig and/or tacrolimus (+rapamycin or mycophenolate mofetil) (GroupA [US Food and Drug Administration-approved regimens], n = 4) or (2) anti-CD40mAb + rapamycin (GroupB, n = 4). All baboons received corticosteroids, interleukin-6R blockade, and tumor necrosis factor-α blockade. Baboons were followed by clinical and laboratory monitoring of kidney function, coagulation, and immune parameters. At euthanasia, morphological and immunohistochemical studies were performed on the kidney grafts.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The median survival in GroupB was 186 days (range 90-260), which was significantly longer than in GroupA; median 14 days (range 12-32) (P < 0.01). Only GroupA baboons developed consumptive coagulopathy and the histopathological features of thrombotic microangiopathic glomerulopathy and interstitial arterial vasculitis.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Recognizing that the pig donors in each group differed in some genetic modifications, these data indicate that maintenance immunosuppression including anti-CD40mAb may be important to prevent pig kidney graft failure.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31283686</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1534-6080</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>10</Month></PubDate></JournalIssue><Title>Transplantation</Title><ISOAbbreviation>Transplantation</ISOAbbreviation></Journal><ArticleTitle>Life-supporting Kidney Xenotransplantation From Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens.</ArticleTitle><Pagination><MedlinePgn>2090-2104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TP.0000000000002796</ELocationID><Abstract><AbstractText Label="BACKGROUND">The aims of this study were to evaluate the efficacy of US Food and Drug Administration-approved drugs in genetically engineered pig-to-baboon kidney xenotransplantation and compare the results with those using an anti-CD40 monoclonal antibody (mAb)-based regimen.</AbstractText><AbstractText Label="METHODS">Ten life-supporting kidney transplants were carried out in baboons using α1,3-galactosyltransferase gene-knockout/CD46 pigs with various other genetic manipulations aimed at controlling coagulation dysregulation. Eight transplants resulted in informative data. Immunosuppressive therapy consisted of induction with antithymocyte globulin and anti-CD20mAb, and maintenance based on either (1) CTLA4-Ig and/or tacrolimus (+rapamycin or mycophenolate mofetil) (GroupA [US Food and Drug Administration-approved regimens], n = 4) or (2) anti-CD40mAb + rapamycin (GroupB, n = 4). All baboons received corticosteroids, interleukin-6R blockade, and tumor necrosis factor-α blockade. Baboons were followed by clinical and laboratory monitoring of kidney function, coagulation, and immune parameters. At euthanasia, morphological and immunohistochemical studies were performed on the kidney grafts.</AbstractText><AbstractText Label="RESULTS">The median survival in GroupB was 186 days (range 90-260), which was significantly longer than in GroupA; median 14 days (range 12-32) (P < 0.01). Only GroupA baboons developed consumptive coagulopathy and the histopathological features of thrombotic microangiopathic glomerulopathy and interstitial arterial vasculitis.</AbstractText><AbstractText Label="CONCLUSIONS">Recognizing that the pig donors in each group differed in some genetic modifications, these data indicate that maintenance immunosuppression including anti-CD40mAb may be important to prevent pig kidney graft failure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Hidetaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foote</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Animal Resources Program, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liaoran</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Edwin C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Division of Laboratory Animal Resources, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuurman</LastName><ForeName>Hendrik Jan</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Schubiomed Consultancy, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hongmin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tector</LastName><ForeName>A Joseph</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhongqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery and Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezzelarab</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovingood</LastName><ForeName>Ray</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Kirklin Clinic Pharmacy, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayares</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Revivicor, Blacksburg, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckhoff</LastName><ForeName>Devin E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David K C</ForeName><Initials>DKC</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwase</LastName><ForeName>Hayato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI090959</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplantation</MedlineTA><NlmUniqueID>0132144</NlmUniqueID><ISSNLinking>0041-1337</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019013">CD40 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497857">CD46 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051916">Membrane Cofactor Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.-</RegistryNumber><NameOfSubstance UI="D005700">Galactosyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.87</RegistryNumber><NameOfSubstance UI="C047006">N-acetyllactosaminide alpha-1,3-galactosyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019013" MajorTopicYN="N">CD40 Antigens</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005700" MajorTopicYN="N">Galactosyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055786" MajorTopicYN="N">Gene Knockout Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006085" MajorTopicYN="N">Graft Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008020" MajorTopicYN="N">Life Support Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051916" MajorTopicYN="N">Membrane Cofactor Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010215" MajorTopicYN="N">Papio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019737" MajorTopicYN="N">Transplants</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31283686</ArticleId><ArticleId IdType="doi">10.1097/TP.0000000000002796</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li><li>République populaire de Chine</li><li>États-Unis</li></country><region><li>Alabama</li><li>Hubei</li><li>Pennsylvanie</li><li>Utrecht (province)</li><li>Virginie</li></region><settlement><li>Utrecht</li><li>Wuhan</li></settlement></list><tree><country name="États-Unis"><region name="Alabama"><name sortKey="Yamamoto, Takayuki" sort="Yamamoto, Takayuki" uniqKey="Yamamoto T" first="Takayuki" last="Yamamoto">Takayuki Yamamoto</name></region><name sortKey="Ayares, David" sort="Ayares, David" uniqKey="Ayares D" first="David" last="Ayares">David Ayares</name><name sortKey="Cooper, David K C" sort="Cooper, David K C" uniqKey="Cooper D" first="David K C" last="Cooper">David K C. Cooper</name><name sortKey="Eckhoff, Devin E" sort="Eckhoff, Devin E" uniqKey="Eckhoff D" first="Devin E" last="Eckhoff">Devin E. Eckhoff</name><name sortKey="Ezzelarab, Mohamed" sort="Ezzelarab, Mohamed" uniqKey="Ezzelarab M" first="Mohamed" last="Ezzelarab">Mohamed Ezzelarab</name><name sortKey="Foote, Jeremy" sort="Foote, Jeremy" uniqKey="Foote J" first="Jeremy" last="Foote">Jeremy Foote</name><name sortKey="Hara, Hidetaka" sort="Hara, Hidetaka" uniqKey="Hara H" first="Hidetaka" last="Hara">Hidetaka Hara</name><name sortKey="Iwase, Hayato" sort="Iwase, Hayato" uniqKey="Iwase H" first="Hayato" last="Iwase">Hayato Iwase</name><name sortKey="Klein, Edwin C" sort="Klein, Edwin C" uniqKey="Klein E" first="Edwin C" last="Klein">Edwin C. Klein</name><name sortKey="Li, Juan" sort="Li, Juan" uniqKey="Li J" first="Juan" last="Li">Juan Li</name><name sortKey="Li, Qi" sort="Li, Qi" uniqKey="Li Q" first="Qi" last="Li">Qi Li</name><name sortKey="Lovingood, Ray" sort="Lovingood, Ray" uniqKey="Lovingood R" first="Ray" last="Lovingood">Ray Lovingood</name><name sortKey="Tector, A Joseph" sort="Tector, A Joseph" uniqKey="Tector A" first="A Joseph" last="Tector">A Joseph Tector</name><name sortKey="Wang, Liaoran" sort="Wang, Liaoran" uniqKey="Wang L" first="Liaoran" last="Wang">Liaoran Wang</name><name sortKey="Zhang, Zhongqiang" sort="Zhang, Zhongqiang" uniqKey="Zhang Z" first="Zhongqiang" last="Zhang">Zhongqiang Zhang</name><name sortKey="Zhou, Hongmin" sort="Zhou, Hongmin" uniqKey="Zhou H" first="Hongmin" last="Zhou">Hongmin Zhou</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Wang, Liaoran" sort="Wang, Liaoran" uniqKey="Wang L" first="Liaoran" last="Wang">Liaoran Wang</name></noRegion><name sortKey="Li, Juan" sort="Li, Juan" uniqKey="Li J" first="Juan" last="Li">Juan Li</name><name sortKey="Li, Qi" sort="Li, Qi" uniqKey="Li Q" first="Qi" last="Li">Qi Li</name><name sortKey="Zhang, Zhongqiang" sort="Zhang, Zhongqiang" uniqKey="Zhang Z" first="Zhongqiang" last="Zhang">Zhongqiang Zhang</name><name sortKey="Zhou, Hongmin" sort="Zhou, Hongmin" uniqKey="Zhou H" first="Hongmin" last="Zhou">Hongmin Zhou</name></country><country name="Pays-Bas"><region name="Utrecht (province)"><name sortKey="Schuurman, Hendrik Jan" sort="Schuurman, Hendrik Jan" uniqKey="Schuurman H" first="Hendrik Jan" last="Schuurman">Hendrik Jan Schuurman</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000300 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000300 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31283686
|texte= Life-supporting Kidney Xenotransplantation From Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31283686" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |